Publications by authors named "Howell Stephen B"

Claim this Profile
P
Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
Himangshu Sonowal, William G Rice, Raphael Bejar, Joo-Yun Byun, Seung Hyun Jung

Cancer Res Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis.
Menghan Fang, Youfen Lin, Chaorong Xue, Kaiqin Sheng, Zegeng Guo

Br J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian Cancer.
Clara Wong, Maria Carmen Mulero, Erika I Barth, Katherine Wang, Xiying Shang

J Pharmacol Exp Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma.
Himangshu Sonowal, William G Rice, Stephen B Howell

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.
William G Rice, Stephen B Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local

Mol Cancer Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer.
Alexander T Wenzel, Devora Champa, Hrishi Venkatesh, Si Sun, Cheng-Yu Tsai

NPJ Syst Biol Appl· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα.
Himangshu Sonowal, Hongying Zhang, William Rice, Stephen B Howell

Biochem Pharmacol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Targeting of Tumor Cells Rich in LGR Stem Cell Receptors.
Songman Yu, Maria Carmen Mulero, Wannan Chen, Xiying Shang, Songyu Tian

Bioconjug Chem· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
Sanghoon Lee, John Jun, William J Kim, Pablo Tamayo, Stephen B Howell

Anticancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide-Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA.
Byungji Kim, Si Sun, Judith A Varner, Stephen B Howell, Erkki Ruoslahti

Adv Mater· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy.
Alessandro Bertucci, Kang-Hoon Kim, Jinyoung Kang, Jonathan M Zuidema, Seo Hyeon Lee

ACS Appl Mater Interfaces· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy.
Maria T Proetto, Cassandra E Callmann, John Cliff, Craig J Szymanski, Dehong Hu

ACS Cent Sci· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su

Mol Cancer Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.
Andrea Local, Hongying Zhang, Khalid D Benbatoul, Peter Folger, Xia Sheng

Mol Cancer Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LGR5 and LGR6 in stem cell biology and ovarian cancer.
Adam J Schindler, Arisa Watanabe, Stephen B Howell

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Danielle A Jandial, William E Brady, Stephen B Howell, Heather A Lankes, Russell J Schilder

Gynecol Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.
Kristin M Bompiani, Cheng-Yu Tsai, Felix P Achatz, Janika K Liebig, Stephen B Howell

Metallomics· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular Delivery of Nanoparticles Revealed with Combined Optical and Isotopic Nanoscopy.
Maria T Proetto, Christopher R Anderton, Dehong Hu, Craig J Szymanski, Zihua Zhu

ACS Nano· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.
Franco M Muggia, Andrea Bonetti, James D Hoeschele, Marcel Rozencweig, Stephen B Howell

J Clin Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).
Cheng-Yu Tsai, Janika K Liebig, Igor F Tsigelny, Stephen B Howell

Metallomics· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin inhibits MEK1/2.
Tetsu Yamamoto, Igor F Tsigelny, Andreas W Götz, Stephen B Howell

Oncotarget· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Kazuki N Sugahara, Pablo Scodeller, Gary B Braun, Tatiana Hurtado de Mendoza, Chisato M Yamazaki

J Control Release· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrin αV control of Cu homeostasis and cisplatin sensitivity.
Xinjian Lin, Xiying Shang, Stephen B Howell

Cell Cycle· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1.
Xinjian Lin, Xiying Shang, Gerald Manorek, Mariama Fofana, Howell Stephen B

Oncoscience· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.
Xiying Shang, Xinjian Lin, Stephen B Howell

Cell Commun Signal· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis